Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Xencor, Inc.
Stanford University
University Hospital, Antwerp
Eli Lilly and Company
AstraZeneca
Xencor, Inc.
University of Southern California
Eli Lilly and Company
Celldex Therapeutics
HiberCell, Inc.
Corvus Pharmaceuticals, Inc.
M.D. Anderson Cancer Center
Canadian Cancer Trials Group
Klus Pharma Inc.
Tempest Therapeutics
Fate Therapeutics
Xencor, Inc.
Evelo Biosciences, Inc.
Nektar Therapeutics
Novartis
Xencor, Inc.
Scripps Health
Ludwig Institute for Cancer Research
Incyte Corporation
Calithera Biosciences, Inc
Incyte Corporation
MacroGenics
Incyte Corporation
MacroGenics
Incyte Corporation
Gilead Sciences
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Novartis
Novartis
Incyte Corporation
Abramson Cancer Center at Penn Medicine
Celgene
Mirror Biologics, Inc.
Stanford University
Pfizer
Mayo Clinic
Swiss Cancer Institute
Kantonsspital Winterthur KSW
Stanford University
National Institutes of Health Clinical Center (CC)
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Radboud University Medical Center
GlaxoSmithKline